Drug intelligence / Profile preview

MED401

Development stage: Preclinical
Lead developer: ADC Therapeutics
Modality: Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics

Overview

MED401 is a preclinical-stage antibody-drug conjugate (ADC) being developed by Medley Therapeutics for the treatment of solid tumors. The therapeutic is designed as a tumor-targeted agent that delivers a cytotoxic payload directly to malignant cells, a strategy intended to enhance anti-tumor activity while reducing off-target effects. MED401 is currently in the IND-enabling phase of development, representing a key oncology candidate in Medley Therapeutics' pipeline alongside their radioligand programs.

Beyond the preview

Go deeper on MED401.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on MED401.

Explore the full profile